LUPRON DEPOT-PED Drug Patent Profile
✉ Email this page to a colleague
When do Lupron Depot-ped patents expire, and what generic alternatives are available?
Lupron Depot-ped is a drug marketed by Abbvie Endocrine Inc and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in LUPRON DEPOT-PED is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lupron Depot-ped
A generic version of LUPRON DEPOT-PED was approved as leuprolide acetate by SANDOZ on August 4th, 1998.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LUPRON DEPOT-PED?
- What are the global sales for LUPRON DEPOT-PED?
- What is Average Wholesale Price for LUPRON DEPOT-PED?
Summary for LUPRON DEPOT-PED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in LUPRON DEPOT-PED? | LUPRON DEPOT-PED excipients list |
| DailyMed Link: | LUPRON DEPOT-PED at DailyMed |
Recent Clinical Trials for LUPRON DEPOT-PED
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | PHASE2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | PHASE2 |
| Zenith Epigenetics | PHASE2 |
